SCHEMBL16632292

SCHEMBL16632292

CCc1nc2cc(N(C)Cc3ccc(OC)cc3)ncc2cc1-c1cc(NC(=O)O)c(F)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
KCNH2 Q12809 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
ABL1 P00519 1/20 0.35
KDR P35968 5/20 0.34
FGFR1 P11362 4/20 0.34
GRM8 O00222 1/20 0.34
GRM6 O15303 1/20 0.34
CACNA1C Q13936 1/20 0.34
GRM2 Q14416 1/20 0.34
GRM3 Q14832 1/20 0.34
ADORA2A P29274 1/20 0.33
LMNA P02545 1/20 0.32
CACNA1B Q00975 1/20 0.32
KRAS P01116 1/20 0.32
RAF1 P04049 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632423 0.94 KDR (0.38) ALDH1A1KCNH2HDAC3HDAC1HDAC2
SCHEMBL16632381 0.92 KDR (0.39) ALDH1A1KCNH2HDAC3HDAC1HDAC2
SCHEMBL15289506 0.90 ABL1 (0.35) KCNH2HDAC3HDAC1HDAC2HDAC10
SCHEMBL16632183 0.89 KDR (0.39) ALDH1A1KCNH2HDAC3HDAC1HDAC2
SCHEMBL15289584 0.89 RAF1 (0.45) ABL1KDRFGFR1LMNAKRAS
SCHEMBL16632505 0.86 KDR (0.46) ALDH1A1KCNH2HDAC3HDAC1HDAC2
SCHEMBL15289510 0.86 BRAF (0.36) ALDH1A1KCNH2HDAC3HDAC1HDAC2
SCHEMBL15289531 0.85 ALDH1A1 (0.39) ALDH1A1HDAC3HDAC1HDAC2HDAC10
SCHEMBL15289585 0.84 BRAF (0.53) HDAC3HDAC1HDAC2HDAC10NCOR2
SCHEMBL15272707 0.83 KDR (0.47) KCNH2HDAC3HDAC1HDAC2HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187474-B2 Raf inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-17 US disclosed
US-20150105367-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105367-A1 RAF INHIBITOR COMPOUNDS BRAF, RAF1, NRAS ALDH1A1 1426/4885KCNH2 2829/4885HDAC3 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.